Search alternatives:
large decrease » larger decrease (Expand Search), marked decrease (Expand Search), large increases (Expand Search)
3 decrease » a decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
i large » ai large (Expand Search), _ large (Expand Search), a large (Expand Search)
Showing 1 - 20 results of 32,791 for search '(((( a ((_ decrease) OR (mean decrease)) ) OR ( _ 3 decrease ))) OR ( i large decrease ))', query time: 1.09s Refine Results
  1. 1
    ECoG timescales decrease during spatial attention.

    ECoG timescales decrease during spatial attention. by Isabel Raposo (21615517)

    Published 2025
    “…The individual values for panel A and C are included in <a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.3003232#pbio.3003232.s005" target="_blank">S2 Data</a>, Experiment 1, 3 and 4 sheets and <a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.3003232#pbio.3003232.s006" target="_blank">S3 Data</a>, respectively.…”
    Save to List
    Saved in:
  2. 2
    The reduced virulence of Δalta1 mutants is not primarily due to a decrease in growth.

    The reduced virulence of Δalta1 mutants is not primarily due to a decrease in growth. by Shuhuan Zhang (748003)

    Published 2025
    Save to List
    Saved in:
  3. 3
    The PRAME-AS knockout cells showed a decrease in migration, proliferation, stemness, and viability.

    The PRAME-AS knockout cells showed a decrease in migration, proliferation, stemness, and viability. by Zahra Hosseininia (22265113)

    Published 2025
    Save to List
    Saved in:
  4. 4
    NSC population and proliferation decrease drastically during the second postnatal week of DG development.

    NSC population and proliferation decrease drastically during the second postnatal week of DG development. by Cristina Medina-Menéndez (21800157)

    Published 2025
    Save to List
    Saved in:
  5. 5
    Naringenin decreases mitochondrial function.

    Naringenin decreases mitochondrial function. by Lauren A. Eanes (20995499)

    Published 2025
    Save to List
    Saved in:
  6. 6
    FBP primarily decreases the protein level of HMGB1 by promoting its lysosomal degradation upon viral infection.

    FBP primarily decreases the protein level of HMGB1 by promoting its lysosomal degradation upon viral infection. by Penghui Hu (695020)

    Published 2024
    Save to List
    Saved in:
  7. 7
    Overview of the six original ACTIV-3/TICO trials.

    Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 8
    Madrasin decreases transcription of protein-coding genes.

    Madrasin decreases transcription of protein-coding genes. by Michael Tellier (8284752)

    Published 2024
    Save to List
    Saved in:
  9. 9
    Madrasin decreases transcription of protein-coding genes.

    Madrasin decreases transcription of protein-coding genes. by Michael Tellier (8284752)

    Published 2024
    Save to List
    Saved in:
  10. 10
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 11
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 12
    <b>Supporting data for manuscript</b> "<b>Voluntary locomotion induces an early and remote hemodynamic decrease in the large cerebral veins</b>"

    <b>Supporting data for manuscript</b> "<b>Voluntary locomotion induces an early and remote hemodynamic decrease in the large cerebral veins</b>" by Kira Shaw (18796168)

    Published 2025
    “…<p dir="ltr">The CSV file 'Eyreetal_DrainingVein_SourceData' contains the averaged time series traces and extracted metrics from individual experiments used across Figures 1-5 in the manuscript "Voluntary locomotion induces an early and remote hemodynamic decrease in the large cerebral veins". …”
    Save to List
    Saved in:
  13. 13
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 14
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 15
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 16
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 17
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 18
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 19
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 20
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: